Search

Your search keyword '"Barbarot S"' showing total 1,288 results
Start Over Author "Barbarot S"
1,288 results on '"Barbarot S"'

108. Identification of three clinical neurofibromatosis 1 subtypes: Latent class analysis of a series of 1351 patients.

Author

Bergqvist, C., Fertitta, L., Ezzedine, K., Jannic, A., Zehou, O., Ferkal, S., Combemale, P., Barbarot, S., Mazereeuw‐Hautier, J., Sbidian, E., Wolkenstein, P., Adamski, Henri, Baumann‐Morel, Clarisse, Bellanné, Christine, Bieth, Eric, Bousquet, Pascal, Brandt, Christian, Balguerie, Xavier, Castelnau, Pierre, and Chaix, Yves

Subjects
TUMOR suppressor genes, NEUROFIBROMATOSIS 1, NEUROFIBROMA, SUPPRESSOR mutation, SYMPTOMS, DISEASE complications
Abstract

Background: Neurofibromatosis 1 (NF1) is one of the most common inherited disorders characterized by mutations in the tumour suppressor gene NF1. Its clinical manifestations are highly variable and unpredictable. A specific NF1 mutation does not predict the severity or complications of the disease. Objective: The objective of this study was to build an empirical classification scheme without any a priori hypotheses to identify the underlying NF1 subtypes that best explain the observed heterogeneity. Methods: We performed latent class analysis (LCA) of 1351 consecutive NF1 patients aged >17 years seen between 2002 and 2014. Data and phenotypic features were collected prospectively on a standardized form. Results: The median age was 36.8 (17–81) years. A three‐class model showed the best fit: 706 (52%) belonged to the LC1 'Cutaneous neurofibromas' class having preferentially cutaneous neurofibromas (99%), plexiform neurofibromas (63%) and blue‐red macules (29%); 593 (44%) belonged to the LC2 'Subcutaneous neurofibromas' class characterized by the presence of at least 10 subcutaneous neurofibromas (21%) and a familial form (77%) and 52 (4%) belonged to the LC3 'Dysmorphic phenotype' class characterized by dysmorphic features (78%) and learning difficulties (87%). Patients in LC1 had a higher likelihood of developing scoliosis (RR = 1.7, 95% confidence interval (CI) [1.2–2.4]). Patients in LC2 were more likely to be men (RR = 1.4, 95% CI [1.1–1.7]). Patients in LC3 were at higher risk of having an optic pathway glioma (RR = 4.8, 95% CI [1.9–11.8]) and epilepsy (RR = 4.5, 95% CI [1.8–11.6]). Conclusion: Our findings invite the performance of a larger cohort study to test whether the various latent classes reflect different underlying genetic modifiers of these phenotypic traits. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

109. European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID‐19 (SARS‐CoV‐2) being treated with systemic medication and biologics

Author

Thyssen, J.P., primary, Vestergaard, C., additional, Barbarot, S., additional, de Bruin‐Weller, M.S., additional, Bieber, T., additional, Taieb, A., additional, Seneschal, J., additional, Cork, M.J., additional, Paul, C., additional, Flohr, C., additional, Weidinger, S., additional, Trzeciak, M., additional, Werfel, T., additional, Heratizadeh, A., additional, Darsow, U., additional, Simon, D., additional, Torrelo, A., additional, Chernyshov, P.V., additional, Stalder, J.‐F., additional, Gelmetti, C., additional, Szalai, Z., additional, Svensson, Å., additional, von Kobyletzki, L.B., additional, De Raeve, L., additional, Fölster‐Holst, R., additional, Christen‐Zaech, S., additional, Hijnen, D.J., additional, Gieler, U., additional, Gutermuth, J., additional, Bangert, C., additional, Spuls, P.I., additional, Kunz, B., additional, Ring, J., additional, Wollenberg, A., additional, and Deleuran, M., additional

Published
2021
Full Text
View/download PDF

115. European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis

Author

Wollenberg, A., Flohr, C., Simon, D., Cork, M.J., Thyssen, J.P., Bieber, T., de Bruin-Weller, M.S., Weidinger, S., Deleuran, M., Taieb, A., Paul, C., Trzeciak, M., Werfel, T., Seneschal, J., Barbarot, S., Darsow, U., Torrelo, A., Stalder, J.-F., Svensson, Å., Hijnen, D., Gelmetti, C., Szalai, Z., Gieler, U., De Raeve, L., Kunz, B., Spuls, P., von Kobyletzki, L.B., Fölster-Holst, R., Chernyshov, P.V., Cristen-Zaech, S., Heratizadeh, A., Ring, J., and Vestergaard, C.

Abstract

Atopic dermatitis (AD) is a complex disease with elevated risk of respiratory comorbidities. Severely affected patients are often treated with immune‐modulating systemic drugs. On March 11th 2020, the World Health Organization declared the 2019 novel coronavirus severe acute respiratory syndrome (SARS‐Cov‐2) epidemic to be a pandemic. The number of cases worldwide is increasing exponentially and poses a major health threat, especially for those who are elderly, immuno‐compromised, or have comorbidities. This also applies to AD patients on systemic immune‐modulating treatment. In these days of uncertainty, reallocation of medical resources, curfew, hoarding, and shutdown of normal social life, patients, caregivers and doctors ask questions regarding the continuation of systemic immune‐modulating treatment of AD patients. The ETFAD decided to address some of these questions here.

Published
2020

118. Acrosyndromes aigus pédiatriques au cours de l’épidémie de COVID-19 : étude des caractéristiques de la cellule familiale

Author

Hubiche, T., primary, Phan, A., additional, Leducq, S., additional, Rapp, J., additional, Fertitta, L., additional, Aubert, H., additional, Barbarot, S., additional, Chiaverini, C., additional, Giraudeau, B., additional, Labarelle, A., additional, Mc Craig, C., additional, Martin, L., additional, Monitor, L., additional, Nicol, I., additional, Piram, M., additional, Bissuel, M., additional, Bellissen, A., additional, Lasek, A., additional, Mallet, S., additional, Vabres, P., additional, and Maruani, A., additional

Published
2020
Full Text
View/download PDF

119. Durées de traitement et post-traitement des traitements systémiques dans une cohorte nationale française d’enfants ayant une dermatite atopique

Author

Chambrelan, E., primary, Barbarot, S., additional, Bekel, L., additional, Poizeau, F., additional, Mahé, E., additional, Puzenat, E., additional, Delaunay, J., additional, Mallet, S., additional, Bessis, D., additional, Maruani, A., additional, Miquel, J., additional, Raison-Peyron, N., additional, Darrieux, L., additional, Abasq, C., additional, Phan, A., additional, Aurélie, D.-T., additional, Kupfer, I., additional, Bonniaud, B., additional, Bouzille, G., additional, Law Ping Man, S., additional, Dupuy, A., additional, and Droitcourt, C., additional

Published
2020
Full Text
View/download PDF

124. Hyperéosinophilie associée au traitement par dupilumab dans la dermatite atopique modérée à sévère : étude rétrospective multicentrique du GREAT

Author

Marcant, P., primary, Balayé, P., additional, Merhi, R., additional, Seneschal, J., additional, Tauber, M., additional, Jendoubi, F., additional, Nosbaum, A., additional, Raison-Peyron, N., additional, Du-Thanh, A., additional, Lasek, A., additional, Ferrier le Bouedec, M.-C., additional, Tetart, F., additional, Valois, A., additional, Lefevre, G., additional, Barbarot, S., additional, Soria, A., additional, Jachiet, M., additional, and Staumont-Sallé, D., additional

Published
2020
Full Text
View/download PDF

125. La majorité des engelures observées durant l’épidémie de COVID-19 ne semblent pas dues à l’infection par le SRAS-Cov-2

Author

Le Cleach, L., primary, Dousset, L., additional, Assier, H., additional, Fourati, S., additional, Barbarot, S., additional, Boulard, C., additional, Bourseau Quetier, C., additional, Cambon, L., additional, Cazanave, C., additional, Colin, A., additional, Kostrzewa, E., additional, Lesort, C., additional, Levy Roy, A., additional, Lombart, F., additional, Marco-Bonnet, J., additional, Monfort, J.B., additional, Samimi, M., additional, Tardieu, M., additional, Wolkenstein, P., additional, Sbidian, E., additional, and Beylot-Barry, M., additional

Published
2020
Full Text
View/download PDF

126. Qualité de vie chez les enfants ayant une malformation capillaire de membre inférieur : données dynamiques sur 5 ans (cohorte nationale multicentrique CONAPE)

Author

Robert, J., primary, Marchand, A., additional, Mazereeuw-Hautier, J., additional, Boccara, O., additional, Martin, L., additional, Chiaverini, C., additional, Beneton, N., additional, Vabres, P., additional, Balguerie, X., additional, Plantin, P., additional, Bessis, D., additional, Barbarot, S., additional, Dadban, A., additional, Droitcourt, C., additional, Morel, B., additional, Leducq, S., additional, Samimi, M., additional, Caille, A., additional, and Maruani, A., additional

Published
2020
Full Text
View/download PDF

127. Impact d’une formation e-learning sur les compétences des pharmaciens dans la prise en charge de l’eczéma atopique : l’expérience POP Training

Author

Stalder, J.-F., primary, Avenel Audran, M., additional, Barbarot, S., additional, Bellon, N., additional, Bodemer, C., additional, Bourrel Bouttaz, M., additional, Chavigny, J.-M., additional, Compain, S., additional, Dimarcq, S., additional, Dreyfus, I., additional, Dufresne, H., additional, Du-Thanh, A., additional, Gardinal Galera, I., additional, Hacard, F., additional, Hadj Rabia, S., additional, Juchet, A., additional, Léandro, F., additional, Mallet, S., additional, Montagnon, A., additional, Nadeau, V., additional, Nonni, J., additional, Ortuno, E., additional, Peyla, L., additional, Sterling, B., additional, Tabélé, C., additional, Tranier, A.-M., additional, Tribouillard, C., additional, Trouillard, A., additional, Verdu, V., additional, Méry, S., additional, and Nosbaum, A., additional

Published
2020
Full Text
View/download PDF

128. Manifestations cutanées au cours l’épidémie de COVID-19 : étude COVID-Skin de la Société française de dermatologie

Author

Guelimi, R., primary, Salle, R., additional, Dousset, L., additional, Assier, H., additional, Fourati, S., additional, Barbarot, S., additional, Boulard, C., additional, Quetier, C. Bourseau, additional, Cambon, L., additional, Cazenave, C., additional, Colin, A., additional, Kostrzewa, E., additional, Lesort, C., additional, Roy, A. Levy, additional, Lombart, F., additional, Marco-Bonnet, J., additional, Monfort, J.-B., additional, Samimi, M., additional, Tardieu, M., additional, Sbidian, E., additional, Wolkenstein, P., additional, Le Cleach, L., additional, and Beylot-Bary, M., additional

Published
2020
Full Text
View/download PDF

133. Propranolol-resistant infantile haemangiomas

Author

Caussé, S., Aubert, H., Saint-Jean, M., Puzenat, E., Bursztejn, A.-C., Eschard, C., Mahé, E., Maruani, A., Mazereeuw-Hautier, J., Dreyfus, I., Miquel, J., Chiaverini, C., Boccara, O., Hadj-Rabia, S., Stalder, J.-F., and Barbarot, S.

Published
2013
Full Text
View/download PDF

136. Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials.

Author

Barbarot, S., Wollenberg, A., Silverberg, J. I., Deleuran, M., Pellacani, G., Armario-Hita, J. C., Chen, Z., Shumel, B., Eckert, L., Gadkari, A., Lu, Y., and Rossi, A. B.

Subjects
*CLINICAL trials, *ATOPIC dermatitis, *DUPILUMAB, *ADULTS
Abstract

Dupilumab, a first-in-class therapy targeting the two key cytokines involved in the persistent underlying inflammatory pathway in atopic dermatitis (AD), is approved for treatment of moderate-to-severe AD in Europe, USA, Japan and several other countries. To assess dupilumab effects on SCORing Atopic Dermatitis (SCORAD) and component scores (objective and subjective SCORAD) over time in adults with moderate-to-severe AD. This post hoc analysis included 2,444 patients in four placebo-controlled, double-blind, randomized, phase 3 trials. SOLO 1 and 2 (NCT02277743; NCT02277769) evaluated 16 weeks of dupilumab monotherapy against placebo. CAFÉ (NCT02755649) and CHRONOS (NCT02260986) evaluated dupilumab with concomitant topical corticosteroids (TCS) against TCS alone for 16 and 52 weeks, respectively. 2,444 patients randomized to treatment in SOLO 1 and 2 (N = 1,379), CAFÉ (N = 325) and CHRONOS (N = 740) were analyzed. Dupilumab treatment significantly improved overall SCORAD and individual components as early as Week 1 or 2, with significant and clinically meaningful differences vs. control through end of treatment (p <.0001). These results occurred irrespective of dupilumab regimen, 300 mg subcutaneously weekly or every 2 weeks. In four large phase 3 trials in adults with moderate-to-severe AD, dupilumab treatment with or without concomitant TCS resulted in rapid and sustained improvements in all SCORAD outcomes vs. placebo or TCS alone. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

142. Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe

Author

Stalder, J.-F., Barbarot, S., Wollenberg, A., Holm, E. A., De Raeve, L., Seidenari, S., Oranje, A., Deleuran, M., Cambazard, F., Svensson, A., Simon, D., Benfeldt, E., Reunala, T., Mazereeuv, J., Boralevi, F., Kunz, B., Misery, L., Mortz, C. G., Darsow, U., Gelmetti, C., Diepgen, T., Ring, J., Moehrenschlager, M., Gieler, U., and Taïeb, A.

Published
2011
Full Text
View/download PDF

144. European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis

Author

Thyssen, J.P., primary, Vestergaard, C., additional, Deleuran, M., additional, Bruin‐Weller, M.S., additional, Bieber, T., additional, Taieb, A., additional, Seneschal, J., additional, Cork, M.J., additional, Paul, C., additional, Flohr, C., additional, Weidinger, S., additional, Trzeciak, M., additional, Werfel, T., additional, Heratizadeh, A., additional, Barbarot, S., additional, Darsow, U., additional, Simon, D., additional, Torrelo, A., additional, Chernyshov, P.V., additional, Stalder, J.‐F., additional, Gelmetti, C., additional, Szalai, Z., additional, Svensson, Å., additional, Kobyletzki, L.B., additional, De Raeve, L., additional, Fölster‐Holst, R., additional, Cristen‐Zaech, S., additional, Hijnen, D., additional, Gieler, U., additional, Ring, J., additional, and Wollenberg, A., additional

Published
2020
Full Text
View/download PDF

145. Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials

Author

Barbarot, S., primary, Wollenberg, A., additional, Silverberg, J. I., additional, Deleuran, M., additional, Pellacani, G., additional, Armario-Hita, J. C., additional, Chen, Z., additional, Shumel, B., additional, Eckert, L., additional, Gadkari, A., additional, Lu, Y., additional, and Rossi, A. B., additional

Published
2020
Full Text
View/download PDF

146. Prescriptions hors AMM (autorisation de mise sur le marché) dans le psoriasis de l’enfant

Author

Mahé, E., primary, Corgibet, F., additional, Maccari, F., additional, Hadj-Rabia, S., additional, Phan, C., additional, Ruer-Mulard, M., additional, Boralévi, F., additional, Barbarot, S., additional, Bursztejn, A.-C., additional, Lahfa, M., additional, Severino-Freire, M., additional, Aubin, F., additional, Barthélémy, H., additional, Amy de la Bretêque, M., additional, and Beauchet, A., additional

Published
2020
Full Text
View/download PDF

147. European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS‐Cov‐2) infection and atopic dermatitis

Author

Wollenberg, A., primary, Flohr, C., additional, Simon, D., additional, Cork, M.J., additional, Thyssen, J.P., additional, Bieber, T., additional, Bruin‐Weller, M.S., additional, Weidinger, S., additional, Deleuran, M., additional, Taieb, A., additional, Paul, C., additional, Trzeciak, M., additional, Werfel, T., additional, Seneschal, J., additional, Barbarot, S., additional, Darsow, U., additional, Torrelo, A., additional, Stalder, J.‐F., additional, Svensson, Å., additional, Hijnen, D., additional, Gelmetti, C., additional, Szalai, Z., additional, Gieler, U., additional, De Raeve, L., additional, Kunz, B., additional, Spuls, P., additional, Kobyletzki, L.B., additional, Fölster‐Holst, R., additional, Chernyshov, P.V., additional, Christen‐Zaech, S., additional, Heratizadeh, A., additional, Ring, J., additional, and Vestergaard, C., additional

Published
2020
Full Text
View/download PDF

148. THU0393 INFLAMMATORY BOWEL DISEASES AMONG SECUKINUMAB-TREATED PATIENTS: 24 CASES FROM THE MISSIL REGISTRY

Author

Letarouilly, J. G., primary, Pariente, B., additional, Staumont-Sallé, D., additional, Goupille, P., additional, Claudepierre, P., additional, Varin, S., additional, Lanot, S., additional, Dernis, E., additional, Pascart, T., additional, Banneville, B., additional, Baudart, P., additional, Gombert, B., additional, Bauer, E., additional, Plastaras, L., additional, Barbarot, S., additional, Felten, R., additional, Le Dantec, L., additional, Sultan-Bichat, N., additional, Girard, C., additional, Constantin, A., additional, Wendling, D., additional, Gaudin, P., additional, Jullien, D., additional, Pham, T., additional, and Flipo, R. M., additional

Published
2020
Full Text
View/download PDF

150. TREatment of ATopic eczema (TREAT) Registry Taskforce: method for comparing the safety of dupilumab with other systemic therapies for moderate‐to‐severe eczema

Author

Bosma, A.L., primary, Spuls, P.I., additional, Garcia‐Doval, I., additional, Naldi, L., additional, Prieto‐Merino, D., additional, Tesch, F., additional, Apfelbacher, C.J., additional, Arents, B.W.M., additional, Barbarot, S., additional, Baselga, E., additional, Deleuran, M., additional, Eichenfield, L.F., additional, Gerbens, L.A.A., additional, Irvine, A.D., additional, Manca, A., additional, Mendes‐Bastos, P., additional, Middelkamp‐Hup, M.A., additional, Roberts, A., additional, Seneschal, J., additional, Svensson, Å., additional, Thyssen, J.P., additional, Torres, T., additional, Vermeulen, F.M., additional, Vestergaard, C., additional, Kobyletzki, L.B., additional, Wall, D., additional, Weidinger, S., additional, Schmitt, J., additional, and Flohr, C., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results